Investigation Into the Correlation of Plasma hs-CRP Concentrations and Cardiovascular Risk in Korean Population - Tabular View

This Tabular View shows the required WHO registration data elements as marked by ^†

Tracking Information

First Received Date ^†

January 7, 2009

Last Updated Date

March 24, 2009

Start Date ^†

March 2009

Current Primary Outcome Measures ^†

Evaluate hs-CRP levels according to risk categories by the NCEP ATP III. [ Time Frame: Within the last 12 months from the date of data entry. ] [ Designated as safety issue: No ]

Original Primary Outcome Measures ^†

Same as current

Change History

Complete list of historical versions of study NCT00819273 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^†

Evaluate a relationship between hs-CRP and each CHD CVD risk factor including LDL-C. [ Time Frame: Within the last 12 months from the date of data entry. ] [ Designated as safety issue: No ]

Original Secondary Outcome Measures ^†

Same as current

Descriptive Information

Brief Title ^†

Investigation Into the Correlation of Plasma hs-CRP Concentrations and Cardiovascular Risk in Korean Population

Official Title ^†

Investigation Into the CorrelAtion of pLasma hs-CRP Concentrations and cardiovascuLar rISk in Korean populaTiOn

Brief Summary

An observational, non-interventional, multi-centre study to provide further information on the utility of test for a predictive marker by investigating the current prevalence of high sensitivity CRP (hs-CRP) testing and characteristics of each CVD risk group.

Detailed Description

Study Phase

Study Type ^†

Observational

Study Design ^†

Cohort, Retrospective

Condition ^†

hsCRP

Intervention ^†

Study Arms / Comparison Groups

patients who have records of clinic visit with circulatory and endocrine internal medicines of nationwide tertiary hospitals within the last one year.

Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status ^†

Recruiting

Estimated Enrollment ^†

1700

Estimated Completion Date

June 2009

Primary Completion Date

Eligibility Criteria ^†

Inclusion Criteria:

Subjects with at least one clinic visit record within the last 12 months from the date of data entry.
Subjects with at least one hs-CRP level measured within the last 12 months from the date of data entry.

Exclusion Criteria:

Use of statins or other lipid-lowering therapies including fibrates, niacin, and bile acid sequestrants in the past 3 months prior to hsCRP measurement
Active inflammatory diseases documented during the period of CRP measurement
Subjects taking immunosuppressants
Findings of chronic inflammation: arthritis, lupus, or inflammatory bowel disease

Gender

Both

Ages

18 Years and older

Accepts Healthy Volunteers

Contacts ^††

Contact: AstraZeneca Clinical Study Information

+82-2188-0800

Location Countries ^†

Korea, Republic of

Expanded Access Status

Administrative Information

NCT ID ^†

NCT00819273

Responsible Party

Hyunah Caroline, Choi / CV TA Physician, AstraZeneca Pharmaceuticals

Secondary IDs ^††

Study Sponsor ^†

AstraZeneca

Collaborators ^††

Investigators ^†

Principal Investigator:

Baek Sanghong, Ph.D.

The Catholic University

Information Provided By

AstraZeneca

Verification Date

March 2009

^† Required WHO trial registration data element.
^†† WHO trial registration data element that is required only if it exists.